DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01), Zacks reports.
DiaMedica Therapeutics Stock Down 13.0 %
Shares of NASDAQ:DMAC opened at $5.21 on Wednesday. The stock has a market cap of $222.78 million, a PE ratio of -9.30 and a beta of 1.52. The company’s fifty day moving average is $5.95 and its 200 day moving average is $5.10. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lifted their target price on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- How to Calculate Return on Investment (ROI)
- 3 Stocks Returning Billions to Shareholders via Buybacks
- What Are Dividend Contenders? Investing in Dividend Contenders
- Tesla: 1 Reason to Love It, 1 Reason to Be Cautious
- Differences Between Momentum Investing and Long Term Investing
- 3 Stocks That Could Win Big From a 10% Cap on Credit Card Rates
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
